Summary of talk:
Influenza disease burden is recognized as one of the major public health problems globally. Much less is known about the economic burden of influenza especially in low-and middle- income countries (LMICs). A recent systematic review on the economic burden of influenza in LMICs suggests that information is scarce and/or incomplete and that there is a lack of standardized approaches for cost evaluations in LMICs. WHO commissioned and publicized a Manual for estimating the economic burden of seasonal influenza to support the standardization of estimates of the economic burden of seasonal influenza across countries. This article aims to describe the rationale of this manual development and opportunities that lie in collecting data to help policymakers estimate the economic burden of seasonal influenza. It describes a manual developed by WHO to help such estimation and also links to relevant literature and tools to ensure robustness of applied methods to assess the economic burden associated with seasonal influenza, including direct medical costs, direct non-medical costs and indirect costs.
Dr. Chaiyakunapruk is a Professor in the School of Pharmacy at Monash University Malaysia and an Associate Professor in the Department of Pharmacy Practice at Naresuan University, Thailand. Dr. Chaiyakunapruk is best known for his expertise in health economics, evidence-based medicine (systematic review and pairwise/network meta-analysis) and outcomes research. He has extensive experience in using large databases to understand epidemiology, health care utilization pattern, and economic burden of disease. Dr. Chaiyakunapruk has applied his methodological skills in various fields including medicine, pharmacy, global health, and health policy and published a total of 180 papers in peer reviewed journals. He has been very active at national, regional, and international levels. He was a co-founder of the ISPOR Asia Consortium (International Society of Pharmacoeconomics and Outcomes Research), ISPOR Thailand Chapter, and Asia Pacific Evidence-based Medicine Network. He currently serves as a publication chair of ISPOR Asia consortium. He is also an adviser of National Essential Drug List Selection Subcommittee of Thailand. He is also a co-author of Thai Health Technology Assessment Guideline. He is actively involved in the National Tobacco Control Policy Working Group, Thailand. He was a member of Advisory board of Research Management, Research and Development Institute, Governmental Pharmaceutical Organization in Thailand. At the international level, he has been working as a consultant for WHO in vaccine-related health economics, malaria control, and pharmaceutical economics, as well as a member of the WHO Respiratory Syncytial Virus Vaccine Technical Advisory Group. He is also a member of the Cochrane reviewers on anesthesia, dermatology, and wound group.